Clinical Trial Search

Phase 3 N=1,199 A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)

Prostate Neoplasms

Primary: Radiographic Progression-Free Survival (PFS) — 33.02; 14.78 Months — p=<0.0001

Janssen Research & Development, LLC Results Oct 2018 27.3% serious AE View details

Phase 3 N=371 Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)

Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma · Gastric Cancer Third Line

Primary: Overall Survival (OS) — 5.0; 4.6 months — p=0.8078

EMD Serono Research & Development Institute, Inc. Results Oct 2018 47.4% serious AE View details

Phase 3 N=1,197 Evaluation of the Safety and Immunogenicity of Three Consistency Lots and a High-Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults (V920-012)

Prevention of Ebola Infection

Primary: Geometric Mean Titer of Anti-ZEBOV Glycoprotein Antibody — 1183.9; 1266.0; 1346.0; 1291.9 EU/mL — p=<0.001

Merck Sharp & Dohme LLC Results Oct 2018 4.0% serious AE View details

Phase 3 N=209 A Study To Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

Primary: Change From Baseline in Disease Activity Score in 28 Joints Using 4 Variables (DAS28-4) (C-Reactive Protein [CRP]) at Week 12 — -2.43; -2.85 units on a scale

Pfizer Results Oct 2018 4.3% serious AE View details

Phase 3 N=754 Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia

Hyperkalemia

Primary: Exponential Rate of Change in Serum Potassium (S-K) Levels During the Initial 48 Hours of Study Drug Treatment. — -0.00128; -0.00187; -0.00205; -0.00280 log(mmol/L)/hour

ZS Pharma, Inc. Results Oct 2018 1.2% serious AE View details

Phase 3 N=127 Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence

Cocaine Dependence

Primary: Three Weeks of Cocaine Abstinence at End of Study — 9; 0 Participants

New York State Psychiatric Institute Results Oct 2018 3.2% serious AE View details

Phase 3 N=9 Darbepoetin Alfa MDS Companion Protocol

Myelodysplastic Syndrome (MDS)

Primary: Number of Participants With Treatment-emergent Adverse Events — 9; 8; 2; 0 Participants

Amgen Results Oct 2018 33.3% serious AE View details

Phase 3 N=10,355 A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Primary: Annual Rate of On-treatment Moderate/Severe Exacerbations Comparing FF/UMEC/VI With UMEC/VI and FF/VI — 0.91; 1.07; 1.21 Exacerbations per participant per year — p=<0.001

GlaxoSmithKline Results Oct 2018 21.4% serious AE View details

Phase 3 N=614 A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)

Type 2 Diabetes Mellitus

Primary: Change From Baseline in A1C at Week 24 — -0.51; -0.36 Percent A1C — p=0.006

Merck Sharp & Dohme LLC Results Oct 2018 3.8% serious AE View details

Phase 3 N=9 Efficacy and Safety of Lomitapide in Japanese Patients With HoFH on Concurrent Lipid-Lowering Therapy

Familial Hypercholesterolemia - Homozygous

Primary: Percent Change in LDL-C — -42.2 Percent change

Aegerion Pharmaceuticals, Inc. Results Oct 2018 5.9% serious AE View details

Phase 3 N=883 A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes

Type 2 Diabetes Mellitus · Inadequate Glycaemic Control

Primary: Change From Baseline in HbA1c at Week 24 — -1.03; -0.63; -0.69 Percentage (%) — p=<0.0001

AstraZeneca Results Oct 2018 2.5% serious AE View details

Phase 3 N=175 A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.

Partial Onset Seizures

Primary: Log Transformed 24-Hour Seizure Rate for All Partial Onset Seizures During the Double-Blind Treatment Phase — 1.69; 1.15; 1.58 seizures per 24 hours — p=0.4606

Pfizer's Upjohn has merged with Mylan to form… Results Oct 2018 2.9% serious AE View details

Phase 3 N=213 A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia

Hemodialysis · Hyperphosphatemia

Primary: Adjusted Mean of Serum Phosphorus Concentrations at the End of Treatment — 5.00; 5.34 mg/dL — p=0.020

Kissei Pharmaceutical Co., Ltd. Results Oct 2018 5.2% serious AE View details

Phase 3 N=1,404 A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo

Relapsing Remitting Multiple Sclerosis

Primary: Total Number of Confirmed Relapses During the Placebo Controlled (PC) Treatment Period Estimated by Negative Binomial Regression — 0.331; 0.505 confirmed relapses…

Teva Branded Pharmaceutical Products R&D, Inc. Results Oct 2018 9.5% serious AE View details

Phase 3 N=161 A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia

Hemodialysis Patients With Hyperphosphatemia

Primary: Incidence of Adverse Events — 152 Participants

Kissei Pharmaceutical Co., Ltd. Results Oct 2018 18.0% serious AE View details